Check out the Option Monster report under "headlines" for this site on Nov 17th re a large option "downside" bet on SDRL...Over 20k contracts....Somebody made out huge today. Probably just a "lucky guess" that the dividend was being omited today...lol!
It's about a lying, or incompetentt, or both, BOD and Officers, and particularly a CEO, who made material false representations to shareholders regarding the stability of the dividend through at least 2016. His head and those of his BOD's who knew or suspected as to what he was actually up to re the dividend policy, or sold stock in mid to late 2014, are going to get mauled by class action lawyers...the SEC...and the Courts.
You just can't do what he did and get away with it. Not in this day and age. Shame on them.
Silver....Same to you my man. You and I have had quite the last two years in the bios... ....TSRX....DRTX...TTPH, and now....CEMP... Also owned/own....RLYP...MGNX....
Traded TKMR during the Ebola craze...Just bought for a flier ARWR...Hep C RNAi stock.
Bought BLUE...34's and took profits at 43...Want to re-enter that name though...Could be huge.
Ditto... KITE Another potential homerun stock....Sold NPSP for close to 10pts and will stay out
of the name pending their FDA decision in Jan...
Still own AKAO....That one needs some news...PR...something! LOL....
Been fun. Cheers and enjoy the Holiday wife your family/friends! GL
Maybe, but probably not. This stock was in all sorts of total return and dividend equity mutual funds.
Since it no longer pays a dividend it must be tossed out of those portfolios. You're talking millions and millions of dollars worth of stock and that doesn't even include private equity or pension funds.
When you go from 19% to zero dividend return in one trading day your stock is done. How do
we classify SDRL now? A growth story? Hardly. How about a "value stock"? Maybe once the
dust settles. Total return stock?...Nope. A lying CEO stock? You betcha, but not sure they have
a fund for that unless it is something like the Maidoff Fund....lol..
Seriously, we have really gotten the shaft with this one, and no institution or fund manager is going to trust them again for many many years to come. This isn't an "oil" story. This is a story about management who were totally clueless, but wanted to keep the stock price up until they could come up with some recovery "plan" that the investment community would believe and not punish the share price for.
Well not being honest in the first place was Cardinal sin #1. Paying too high of a dividend under the circumstances was #2. Not gradually cutting it over time, instead of all at once, was #3. Then the big one....Lying to shareholders that the dividend was secure through 2016...That one is unforgiveable.
Lawyers are going to have a field day come Monday....
The CEO blantly lied and misrepresented the financial situation at SDRL. When he said over and over the dividend was good through 2015, then omitts it entirely, something is very wrong at the company. Holding my position as no sense selling it down at these levels, (was there before back in 2009 and recovered to $53), but the lawyers are going to pile on just as soon as they're done eating turkey!
Gives good background on the stock and their lead antibiotic with Phase 3 first line data expected Q1/2015.
Says they expect the results to be positive and CEMP is one of a few antibiotics to be able to be used in a
step down oral formula version to treat pneumonia that has a far superior safety profile to the comparator antibiotic. Says company worth at least 750 million and possibly alot more in a buyout situation.
Read it if you get a chance. Both trials did very well for both companies. Looks like ZSPH had a lower bar to achieve with their trial people with potasium serum rates from 3.9 to 4.6 mols, and RLYP from 4.5 to 5.6. No subjects were above 6 mol. ZSPH combined trials were much larger than RLYP's but shorter in duration (28 days). Side effects for both were good. Question as to how long the drugs remain effective if used for months on end is a question as are any material side effects over prolonged use. Both look like they will get approved IMHO. ZSPH has a faster take up profile with their drug (24hrs) then RLYPs (minimum 48 hrs), and a response rate of 96% versus 76% for RLYP, but again the bar for ZSPH was much lower than that for
Now a little higher than the close on Sept 19th, which is the day you sold.... Doin't make the mistake of being stubborn and watching this one go to 45 without you. FDA approval then a possible buyout IMHO.. 2015 should be a major year for shareholders in this company... Going to rock our worlds in 2 0 1 5 !!
Come back to the party or regret that you didn't! LOL!
Looks like more competition in the delivery area is on the way...
Mohn...See how stuff in print skews the meaning, I read your earlier post to mean you invested in three stocks and they didn't do well so you don't have any money left to invest...LOL! GL to you and especially with CEMP as I own it very large too! Owned TTPH single digits and sold and did very well. ACRX never owned...
Yes...It is the delivery system. But things are changing. ALNY is a $70 company so there must be some validity to the approach. TKMR and ARWR both hold promise. RXII is a very small RNAi cap #$%$ shoot, but has a delivery system using a penetrating single cell approach, and not an independent delivery system.
Hi Silver.... Just looking #$%$t comp#$%$r#$%$ble buyout levels for #$%$ntibiotic comp#$%$nies th#$%$t we've owned like TSRX....DRTX..... $24 to me seems to be the right level...Even TTPH h#$%$s #$%$ current m#$%$rket v#$%$lue of
#$%$round 700 million, so CEMP from 650-700 million would be right in there...
Never heard of ACRX, but the other two your mentioned I owned/own (CEMP and TTPH) and they have either come close to doubling ,or did even better than that (TTPH). Add with TSRX and DRTX both buyouts, the entire field has been on fire. And you have no funds? Baffling. Get a new financial advisor! LOL...
Who cares what people did or didn#$%$ do during the pre APPL announcement run up. We all had the chance to sell over $18 and didn#$%$. Hype or not, it was there, and the fact is we held, and others didn#$%$. So what? Maybe it was greed or simply that we felt in the next two years the company will be worth a heck of alot more. Time will tell who was right. No sense though re-hasing ancient history. Doesn#$%$ put a dime in anyones pocket...
Not always smart to take gains on the way up...Just ask all the holders in DRTX who sold on the way up
to $16, then missed out on the $24 buyout a few months later.... Ditto holders in TTPH who sold on the way up to $15 then missed the ride to $24. CEMP has $24 written all over it , and whomever ends up with them is getting a bargin too!
Hanna...And if he and the other insiders want to send "a message" to shareholders, the best way to do that would be for each to buy 50,000 shares right at these levels and then announce that! LOL....Talk is still the cheapest commodity on the planet Earth.....
Hanna....the term "stimulated discussions" is an often much too used term with ultra small bios like RXII to impart potential partnering or other sort of beneficial arrangement with some unmentioned big pharma. Classic small bio BS frankly. Stirs up hopes which nine times out of ten...never happen. If you're having discussions you wait until something material happens that can be announced publicly. Discussions are
like "potential"...Can't take it to the bank.
Latest Phase 3 data presentation at ASN Meeting today. Patiromer had no material safety issue. The drug was well toleratged. Rapid take up of drug within first 48hrs.. Met all endpoints of study. ASN presentation today. Most notably the drug obtained stat significance in treatment within the first 48 hours.
ZSPH missed on one of their secondary endpoints in their latest Phase 3 study announced also at the
We got the edge here gang!! Hang tight. We have a real winner IMHO........Plus we're six months ahead...at
least, in the approval process!